Media

FeaturesMay 07, 2021

Novamind Expands Footprint of Psychedelic Clinics

Our CEO Yaron Conforti and CMO Reid Robison discuss the news of our clinic expansion and how this further develops our model for scaling across the U.S.

OpinionMay 06, 2021

How Modern Psychedelics Began with a Bike Ride

On April 19, 1943, chemist Albert Hofmann took .00005 teaspoons of LSD. As he rode his bicycle home, he realized that the world had just changed. By Novamind CMO, Dr. Reid Robison and Kirsten Hirst.

FeaturesMay 05, 2021

Pierre Bou-Mansour Discusses the Initial Phase of Novamind’s National Expansion Strategy

Our Chief Operating Officer speaks with the Wall Street Reporter about our clinic expansion, the key drivers of our growth, and the importance of set and setting in our clinics.

FeaturesApril 21, 2021

Why Merck Chose Novamind to Lead a Groundbreaking Study

Our CEO and CMO spoke with Streetwise Reports about how Cedar Clinical Research is positioned to develop a new option for treatment-resistant depression.

FeaturesApril 19, 2021

Dr. Reid Robison on the Science of Psychedelics

Leafly interviews Novamind’s CMO about how these compounds influence our mind on a molecular level.

FeaturesApril 17, 2021

Our CEO Discusses the Future of Mental Healthcare on SNN

Yaron Conforti speaks alongside other industry leaders about the treatment models Novamind is working with today, and the ambitious clinic expansions we’re planning for the very near future.